Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Phase I/II Study Evaluating the Efficacy and Toxicity of Imatinib in Adult Patients With Aggressive Fibromatosis That Cannot be Treated by Surgery or Curative Radiotherapy

NCT00287846 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT00287846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00287846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Phase I/II Study Evaluating the Efficacy and Toxicity of Imatinib in Adult Patients With Aggressive Fibromatosis That Cannot be Treated by Surgery or Curative Radiotherapy
Lead sponsor
UNICANCER
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2004
Completion date
June 30, 2010
Enrollment
40 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

desmoid tumor